Previous close | 0.8892 |
Open | 0.8800 |
Bid | 0.8794 x 200 |
Ask | 0.8926 x 300 |
Day's range | 0.8800 - 0.9100 |
52-week range | 0.6500 - 1.5500 |
Volume | |
Avg. volume | 2,188,198 |
Market cap | 357.527M |
Beta (5Y monthly) | 2.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.08 |
-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific S
Amarin ( NASDAQ:AMRN ) Full Year 2023 Results Key Financial Results Revenue: US$306.9m (down 17% from FY 2022). Net...
It's been a sad week for Amarin Corporation plc ( NASDAQ:AMRN ), who've watched their investment drop 11% to US$1.06 in...